OBJECTIVE: The objective of this study was to investigate the clinical use of a novel whole-body magnetic resonance imaging (MRI) system for comprehensive assessment of tumor spread in clinical routine. MATERIAL AND METHODS: Sixty-five patients with different tumors with known metastatic disease and 6 healthy volunteers were included. High-resolution MRI from head to toe was performed using multiple phased-array surface coil elements, 24 independent receiver channels, and an integrated parallel acquisition technique (iPAT). A total room time of less than 60 minutes was required. Whole-body MRI and conventional spiral computed tomography (CT) were independently evaluated and compared in terms of feasibility, location/number of detected metastases, and therapeutic relevance. RESULTS: Whole-body MRI was successfully performed in 68 of 71 subjects. Compared with CT, more metastases were detected by MRI in 11 of 63 patients (17%), particularly in brain, liver, spleen, lymph nodes, bone marrow, muscle, and subcutaneous fat tissue. According to these findings, therapy had to be modified in 6 of 63 patients (10%). CONCLUSIONS: High-resolution whole-body MRI is feasible in clinical routine within 1 single examination and offers great potential for fast assessment of individual tumor spread and total tumor burden.
OBJECTIVE: The objective of this study was to investigate the clinical use of a novel whole-body magnetic resonance imaging (MRI) system for comprehensive assessment of tumor spread in clinical routine. MATERIAL AND METHODS: Sixty-five patients with different tumors with known metastatic disease and 6 healthy volunteers were included. High-resolution MRI from head to toe was performed using multiple phased-array surface coil elements, 24 independent receiver channels, and an integrated parallel acquisition technique (iPAT). A total room time of less than 60 minutes was required. Whole-body MRI and conventional spiral computed tomography (CT) were independently evaluated and compared in terms of feasibility, location/number of detected metastases, and therapeutic relevance. RESULTS: Whole-body MRI was successfully performed in 68 of 71 subjects. Compared with CT, more metastases were detected by MRI in 11 of 63 patients (17%), particularly in brain, liver, spleen, lymph nodes, bone marrow, muscle, and subcutaneous fat tissue. According to these findings, therapy had to be modified in 6 of 63 patients (10%). CONCLUSIONS: High-resolution whole-body MRI is feasible in clinical routine within 1 single examination and offers great potential for fast assessment of individual tumor spread and total tumor burden.
Authors: C Plathow; M Walz; M P Lichy; P Aschoff; C Pfannenberg; H Bock; S M Eschmann; C D Claussen; H P Schlemmer Journal: Radiologe Date: 2008-04 Impact factor: 0.635
Authors: Nadir Ghanem; Christian Lohrmann; Monika Engelhardt; Gregor Pache; Markus Uhl; Ulrich Saueressig; Elmar Kotter; Mathias Langer Journal: Eur Radiol Date: 2006-02-04 Impact factor: 5.315
Authors: M P Lichy; C Mueller-Horvat; V Jellus; W Horger; M Horger; C Pfannenberg; B Kiefer; C D Claussen; H P Schlemmer Journal: Eur Radiol Date: 2008-05-29 Impact factor: 5.315
Authors: Hannah Bainbridge; Ahmed Salem; Rob H N Tijssen; Michael Dubec; Andreas Wetscherek; Corinne Van Es; Jose Belderbos; Corinne Faivre-Finn; Fiona McDonald Journal: Transl Lung Cancer Res Date: 2017-12